Top Markets
Coin of the day
Pharma Equity Group A/S Pharma Equity Group A/S

Pharma Equity Group A/S

PEG
Rank in Stocks #30414
Operating from Hørsholm, Denmark, Pharma Equity Group A/S is an investment firm... Operating from Hørsholm, Denmark, Pharma Equity Group A/S is an investment firm primarily focused on the life sciences industry. The company strategically provides early-stage capital to ventures that are developing advanced technologies and treatments designed to improve human health and elevate the quality of life.
Share Price
$0.01378149
Last synced: 2026-08-18
Market Cap
$16.92M
Change (1 day)
-3.13%
Change (1 year)
-34.10%
Country
DK
Trade Pharma Equity Group A/S (PEG)

Category

P/E ratio for Pharma Equity Group A/S (PEG)
P/E ratio as of 2026 TTM: 0
According to Pharma Equity Group A/S latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Pharma Equity Group A/S from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
29.20 -
US
30.62 -
NL
32.46 -
AU
- -
CH
18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.